Literature DB >> 11824654

Contrast sensitivity function in children: normalized notation for the assessment and diagnosis of diseases.

R Montés-Micó1, T Ferrer-Blasco.   

Abstract

The purpose of this article is to describe a normalized notation for the assessment of the contrast sensitivity in children. This notation is obtained dividing the log contrast sensitivity value found in a patient by the corresponding normative contrast sensitivity data. The ratio obtained describes the contrast sensitivity of a patient facilitating its understanding, assessment and consequently effective communications. This article shows the normalized notation developed for children aged from 3 to 7 years old. An evaluation of the contrast sensitivity in healthy and amblyopic patients has been shown in order to explain the procedure to follow. The use of normalized notation in clinical procedures will provide to the clinician a better understanding of the results and the changes over time as well by comparison in the assessment of an ocular disease.

Entities:  

Mesh:

Year:  2001        PMID: 11824654     DOI: 10.1023/a:1013082523019

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  18 in total

1.  Normative contrast sensitivity data for young children.

Authors:  J E Scharre; S A Cotter; S S Block; S A Kelly
Journal:  Optom Vis Sci       Date:  1990-11       Impact factor: 1.973

2.  Contrast sensitivity in amblyopia. I. Changes during CAM treatment.

Authors:  P U Koskela
Journal:  Acta Ophthalmol (Copenh)       Date:  1986-06

3.  Subtle disturbances of vision after optic neuritis elicited by studying contrast sensitivity.

Authors:  R L Zimmern; F W Campbell; I M Wilkinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-05       Impact factor: 10.154

4.  Contrast sensitivity function of preschool children.

Authors:  J Atkinson; J French; O Braddick
Journal:  Br J Ophthalmol       Date:  1981-08       Impact factor: 4.638

5.  Contrast sensitivity in amblyopia. II. Changes during pleoptic treatment.

Authors:  P U Koskela
Journal:  Acta Ophthalmol (Copenh)       Date:  1986-10

6.  Contrast sensitivity in amblyopia. IV. Assessment of vision using vertical and horizontal gratings and optotypes at different contrast levels.

Authors:  P U Koskela; L Hyvärinen
Journal:  Acta Ophthalmol (Copenh)       Date:  1986-10

7.  Contrast sensitivity in amblyopia. III. Effect of occlusion.

Authors:  P U Koskela; L Hyvärinen
Journal:  Acta Ophthalmol (Copenh)       Date:  1986-08

8.  Contrast sensitivity in children with strabismic and anisometropic amblyopia. A study of the effect of treatment.

Authors:  J Sjöstrand
Journal:  Acta Ophthalmol (Copenh)       Date:  1981-02

9.  Visual acuity and contrast sensitivity in patients with cerebral lesions.

Authors:  I Bodis-Wollner
Journal:  Science       Date:  1972-11-17       Impact factor: 47.728

10.  Mesopic contrast sensitivity function after excimer laser photorefractive keratectomy.

Authors:  Robert Montés-Micó; W Neil Charman
Journal:  J Refract Surg       Date:  2002 Jan-Feb       Impact factor: 3.573

View more
  4 in total

1.  Using 10AFC to further improve the efficiency of the quick CSF method.

Authors:  Fang Hou; Luis Lesmes; Peter Bex; Michael Dorr; Zhong-Lin Lu
Journal:  J Vis       Date:  2015       Impact factor: 2.240

2.  qCSF in clinical application: efficient characterization and classification of contrast sensitivity functions in amblyopia.

Authors:  Fang Hou; Chang-Bing Huang; Luis Lesmes; Li-Xia Feng; Liming Tao; Yi-Feng Zhou; Zhong-Lin Lu
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-19       Impact factor: 4.799

3.  The awareness of amblyopia among parents in Saudi Arabia.

Authors:  Ali M Alsaqr; Ali M Masmali
Journal:  Ther Adv Ophthalmol       Date:  2019-08-08

4.  Evaluating the performance of the quick CSF method in detecting contrast sensitivity function changes.

Authors:  Fang Hou; Luis Andres Lesmes; Woojae Kim; Hairong Gu; Mark A Pitt; Jay I Myung; Zhong-Lin Lu
Journal:  J Vis       Date:  2016       Impact factor: 2.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.